Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;10(1):67-75.
doi: 10.1177/1756285616671887. Epub 2016 Oct 19.

Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis

Jana Lizrova Preiningerova  1 , Marta Vachova  2
Affiliations
Review

Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis

Jana Lizrova Preiningerova et al. Ther Adv Neurol Disord. 2017 Jan.

Abstract

Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56bright natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrast-enhanced lesions on brain magnetic resonance imaging. Treatment with DAC HYP had efficacy superior to treatment with weekly injections of interferon β1a. This review summarizes the development of and clinical experience with daclizumab in MS.

Keywords: CD25; daclizumab; interleukin 2; multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Bielekova B. (2013) Daclizumab therapy for multiple sclerosis. Neurotherapeutics 10: 55–67. - PMC - PubMed
    1. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T., et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103: 5941–5946. - PMC - PubMed
    1. Bielekova B., Howard T., Packer A., Richert N., Blevins G., Ohayon J., et al. (2009) Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66: 483–489. - PMC - PubMed
    1. Bielekova B., Richert N., Herman M., Ohayon J., Waldmann T., McFarland H., et al. (2011) Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 77: 1877–1886. - PMC - PubMed
    1. Bielekova B., Richert N., Howard T., Blevins G., Markovic-Plese S., McCartin J., et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 101: 8705–8708. - PMC - PubMed

LinkOut - more resources